Semaglutide is a synthetic and longer-lasting version of glucagon-like peptide 1 developed by the company Novo Nordisk. GLP-1 and similar hormones help regulate our hunger and metabolism, often by affecting the release of other hormones such as insulin. As a result, GLP-1-basedhave been used for over a decade to help people manage their type 2 diabetes.
demand soon led to shortages of the drug. This demand has also led to shortages of Ozempic, the lower-dose brand of semaglutide approved for diabetes, as doctors began to prescribe it off-label for weight loss. Novo Nordisk has predictably disavowed the use of compounded semaglutide, stating that they do not sell the active ingredient to these pharmacies. On Tuesday, the FDA issued its own
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen: